|
|
|
|
| LEADER |
02150nmm a2200349 u 4500 |
| 001 |
EB000667332 |
| 003 |
EBX01000000000000000520414 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642600616
|
| 100 |
1 |
|
|a Clarke, Michael J.
|e [editor]
|
| 245 |
0 |
0 |
|a Metallopharmaceuticals II
|h Elektronische Ressource
|b Diagnosis and Therapy
|c edited by Michael J. Clarke, Peter J. Sadler
|
| 250 |
|
|
|a 1st ed. 1999
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 1999, 1999
|
| 300 |
|
|
|a X, 216 p
|b online resource
|
| 505 |
0 |
|
|a Magnetic Resonance Imaging (MRI) Contrast Agents -- Metalloradiopharmaceuticals -- Polyoxometalates and Fullerenes as Anti-HIV Agents -- Vanadium-Containing Insulin Drugs -- Bismuth Antiulcer Complexes -- Chrysotherapy: Gold-Drug Metabolism and Immunochemistry
|
| 653 |
|
|
|a Inorganic chemistry
|
| 653 |
|
|
|a Medicine / Research
|
| 653 |
|
|
|a Biology / Research
|
| 653 |
|
|
|a Inorganic Chemistry
|
| 653 |
|
|
|a Biochemistry
|
| 653 |
|
|
|a Biomedical Research
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Sadler, Peter J.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Topics in Biological Inorganic Chemistry
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-60061-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-60061-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 572
|
| 520 |
|
|
|a Inorganic compounds offer much scope for the design of novel and therapeutic agents. The widespread use of paramagnetic metal complexes as effective contrast agents for magentic resonsance imaging (e.g. Gd) demonstrates that the toxicity of metals can be finely controlled via the approriate choice of ligands. The succcessful targeting of radioisotopes again depends on ligand design and metal oxidation state. Bismuth and gold complexes have long been used in medicine but only recently have advances been made in understanding the molecular basis of their mechanism of action. New areas with clinical potential include the use of polyoxometallates and fullerenes as antiviral agents and vanadium complexes as insulin mimetics
|